ArticleBMC gastroenterology2024
Prognostic factors and adjuvant chemotherapy efficacy in stage I gastric cancer patients: a retrospective analysis.
Article in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor index predicts recurrences of patients with pathological stage Ⅰ gastric cancer after radical surgical resection.BMC cancer · 2025Article
- A prognostic nomogram utilized lymph node ratio for signet ring cell gastric cancer patients post-surgery.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough stage I gastric cancer (GC) presents a favorable survival rate, outcomes for patients experiencing recurrence remain poor. This research focuses on assessing the prognosis and identifying risk factors for stage I GC patients, further assessing the necessity of adjuvant chemotherapy (AC).
methodsThe study involved a retrospective analysis of 902 patients with stage I GC who received curative resection from November 2010 to December 2020. Independent prognostic factors were identified using multivariate Cox regression analysis. Kaplan-Meier analysis was employed to compare recurrence-free survival (RFS) and disease-specific survival (DSS) across different groups.
resultsDuring follow-up, 47 patients (5.2%) experienced recurrence or death, with the 3-, 5-, and 10-year survival rates exceeding 90%. Age ≥ 65 years and pT2 stage were independently associated with decreased RFS, while age ≥ 65 years, pT2 stage, and tumor diameter ≥ 5 cm was significantly associated with decreased DSS. Patients with an increasing number of risk factors exhibited lower 5-year RFS [97.4% (risk factors = 0) vs. 91.3% (risk factors = 1) vs. 85.0% (risk factors = 2) vs. 63.6% (risk factors = 3); P < 0.001] and DSS [97.5% (risk factors = 0) vs. 92.7% (risk factors = 1) vs. 85.1% (risk factors = 2) vs. 72.9% (risk factors = 3); P < 0.001]. The AC group had lower DSS for patients without risk factors than the non-AC group. However, there was no significant difference in survival outcomes among patients with risk factors between the AC and non-AC groups.
conclusionStage I GC patients exhibited excellent long-term outcomes post-curative resection. Independent prognostic factors included age, pT stage, and tumor diameter. AC failed to provide any additional survival advantage for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.